Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification and localization of integrated HIV-1 in memory and naïve CD4+ T cells from adolescents and young adults with perinatally-acquired HIV-1.

PLoS pathogens·2026
Same author

Genetic and transcriptomic signatures of host control in HIV-1 infection.

Retrovirology·2026
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Optimizing methods for virome analysis based on studies of a synthetic viral community.

mSystems·2026
Same author

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.

The Journal of infectious diseases·2026
Same author

LVV SMRTcap reveals extensive proviral variation in lentiviral vector-transduced CAR T cells.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 20, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered

Angela Ciuffi1, Tracy L Diamond, Young Hwang

  • 1Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6076, USA.

Human Gene Therapy
|September 16, 2006
PubMed
Summary

Researchers explored using artificial tethering to control retroviral DNA integration site selection. This method could improve safety in gene therapy by guiding integration to specific DNA locations.

More Related Videos

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites
09:31

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites

Published on: March 22, 2016

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites
14:27

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites

Published on: November 14, 2018

Related Experiment Videos

Last Updated: Jul 20, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites
09:31

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites

Published on: March 22, 2016

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites
14:27

CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites

Published on: November 14, 2018

Area of Science:

  • Molecular Biology
  • Virology
  • Gene Therapy

Background:

  • Retroviral integration mechanisms are crucial for gene therapy safety.
  • Adverse clinical events have highlighted the need to control retroviral integration sites.
  • HIV DNA integration typically favors active cellular transcription units.

Purpose of the Study:

  • To investigate artificial tethering for constraining retroviral integration site selection.
  • To explore the role of LEDGF/p75 in retroviral DNA integration targeting.
  • To provide proof of concept for engineering protein-protein interactions to control integration.

Main Methods:

  • Constructed fusions of LEDGF/p75 (or its IN-binding domain) with a DNA-binding protein (lambdaR).
  • Analyzed the effect of these fusions on HIV integrase (IN) strand transfer activity in vitro.
  • Used an in vitro model to study integration site selection.

Main Results:

  • LEDGF/p75 binds to HIV integrase (IN), suggesting a tethering mechanism for integration targeting.
  • Depleting LEDGF/p75 reduced integration within transcription units.
  • LambdaR-LEDGF/p75 fusions increased IN strand transfer near lambdaR-binding sites in vitro.

Conclusions:

  • Direct interaction between LEDGF/p75 and IN mediates targeting via tethering.
  • Protein-protein interactions can be engineered to control retroviral integration site selection.
  • This approach offers potential for enhanced safety in human gene therapy.